Form 4: Dyne Therapeutics CFO Sells Shares for Tax Withholding

Dyne Therapeutics CFO Erick Lucera sold 5,727 shares of common stock for $18.64 per share to cover tax withholding obligations related to vested restricted stock units.

Summary

• Erick Lucera, Chief Financial Officer of Dyne Therapeutics, Inc., reported a transaction on April 1, 2026.
• He sold 5,727 shares of common stock at a weighted average price of $18.64 per share.
• These shares were sold to satisfy tax withholding obligations upon the vesting of restricted stock units granted on March 31, 2025.
• The sale was executed under a pre-arranged contract consistent with Rule 10b5-1(c) for affirmative defense.
• Following this transaction, Lucera beneficially owns 125,373 shares, which includes 114,575 unvested RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is a routine, pre-planned transaction for tax purposes and not indicative of a change in the executive's outlook on the company.

Positives

• The transaction was conducted under a Rule 10b5-1(c) plan, indicating pre-planned and compliant share sales.
• The sale was for tax withholding purposes, a standard and expected event upon vesting of equity awards.
• The CFO retains a significant beneficial ownership of 125,373 shares, demonstrating continued commitment.

Negatives

• A portion of the CFO's equity was sold, reducing direct holdings.

Risks

• The filing does not explicitly mention any new or emerging risks.
• Potential future sales under the 10b5-1 plan could impact share availability.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Management Comments

• The sale was automatically executed to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• The automatic sale is provided for in a restricted stock unit agreement constituting a 'binding contract' consistent with the affirmative defense to liability under Rule 10b5-1.
• The sale does not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and directors, detailing changes in their beneficial ownership of company stock. Such transactions, especially those related to tax withholding under Rule 10b5-1 plans, are common and generally not indicative of a negative view on the company's prospects, provided they are pre-planned and transparent.

Stakeholder Impact

• Shareholders: The sale is pre-planned and for tax purposes, so it is unlikely to have a significant direct impact on the share price or investor sentiment, beyond the routine nature of such filings.

Next Steps

• Continued monitoring of insider transactions for any discretionary sales or purchases.

Key Dates

Keywords

Form 4, Dyne Therapeutics, Erick Lucera, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Rule 10b5-1, Beneficial Ownership